Pharmaceutical

Emergent wins $235.8m US defence contract for Anthrax vaccine

The US Department of Defense procurement contract for Emergent’s BioThrax is comprised of an initial five-year base agreement.

Jan 13, 2024 - 18:00
Emergent wins $235.8m US defence contract for Anthrax vaccine
The US Department of Defense procurement contract for Emergent’s BioThrax is comprised of an initial five-year base agreement.
Read the original article

Tags:

Previous Article

Obesity disease management needs to be revolutionised

Next Article

Santhera’s Agamree becomes first approved treatment in UK for all DMD patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI insight at BIO, Google and Mayo Clinic’s latest effort, & $13 million for health workforce tech

AI insight at BIO, Google and Mayo Clinic’s latest effo...

Jun 8, 2023

FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy 

FDA accepts Mesoblast’s latest BLA for paediatric GvHD ...

Jul 24, 2024

Verve Therapeutics and Lilly partner to advance gene editing programme

Verve Therapeutics and Lilly partner to advance gene ed...

Jun 15, 2023